Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABEO Abeona Therapeutics	$6.65 -0.9%	$6.14	$3.93 ▼ $7.32	$343.26M	1.51	1.07 million shs	527,217 shs
AURA Aura Biosciences	$7.06 +0.9%	$6.37	$4.34 ▼ $12.38	$351.88M	0.45	199,231 shs	126,764 shs
CYRX CryoPort	$7.98 +2.2%	$6.87	$4.58 ▼ $9.66	$391.57M	1.89	440,149 shs	604,880 shs
IMUX Immunic	$1.07 +7.3%	$0.82	$0.56 ▼ $2.11	$95.53M	1.49	1.02 million shs	1.97 million shs

Beginner's Guide To Retirement Stocks

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABEO Abeona Therapeutics	+2.91%	+7.19%	+15.49%	+24.49%	+30.80%
AURA Aura Biosciences	+3.40%	+0.72%	+13.82%	+26.81%	-25.85%
CYRX CryoPort	+5.11%	+4.83%	+19.05%	+32.60%	-13.51%
IMUX Immunic	+6.51%	+11.30%	+40.82%	-12.54%	-31.71%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ABEO Abeona Therapeutics	3.6772 of 5 stars	3.5	1.0	4.5	1.4	2.5	0.0
AURA Aura Biosciences	2.7194 of 5 stars	3.6	1.0	0.0	3.4	3.3	0.0
CYRX CryoPort	2.0433 of 5 stars	3.4	1.0	0.0	2.8	2.5	0.0
IMUX Immunic	2.168 of 5 stars	3.6	1.0	0.0	1.1	2.5	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ABEO Abeona Therapeutics	3.00	Buy	$19.25	189.47% Upside
AURA Aura Biosciences	3.25	Buy	$22.00	211.61% Upside
CYRX CryoPort	2.78	Moderate Buy	$11.11	39.24% Upside
IMUX Immunic	3.29	Buy	$7.50	600.93% Upside

Current Analyst Ratings Breakdown

Latest IMUX, ABEO, CYRX, and AURA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/22/2025	CYRX CryoPort	Stephens Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Overweight	$13.00
7/14/2025	ABEO Abeona Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00
7/7/2025	CYRX CryoPort	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$13.00 ➝ $10.00
6/25/2025	IMUX Immunic	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00
6/5/2025	IMUX Immunic	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00
6/2/2025	ABEO Abeona Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$19.00
5/29/2025	IMUX Immunic	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$17.00 ➝ $10.00
5/28/2025	AURA Aura Biosciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Buy	$22.00
5/23/2025	AURA Aura Biosciences	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$19.00
5/23/2025	IMUX Immunic	B. Riley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$6.00 ➝ $5.00
5/16/2025	ABEO Abeona Therapeutics	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$21.00 ➝ $20.00

(Data available from 7/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ABEO Abeona Therapeutics	$3.50M	97.20	N/A	N/A	$1.01 per share	6.58
AURA Aura Biosciences	N/A	N/A	N/A	N/A	$3.04 per share	N/A
CYRX CryoPort	$232.13M	1.72	N/A	N/A	$7.44 per share	1.07
IMUX Immunic	N/A	N/A	N/A	N/A	$0.20 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ABEO Abeona Therapeutics	-$63.73M	-$1.27	N/A	N/A	N/A	N/A	-118.82%	-52.48%	8/11/2025 (Estimated)
AURA Aura Biosciences	-$86.92M	-$1.90	N/A	N/A	N/A	N/A	-58.63%	-49.74%	8/14/2025 (Estimated)
CYRX CryoPort	-$114.76M	-$2.34	N/A	N/A	N/A	-50.15%	-11.03%	-5.54%	8/5/2025 (Estimated)
IMUX Immunic	-$100.51M	-$1.23	N/A	N/A	N/A	N/A	-326.95%	-181.34%	8/6/2025 (Estimated)

Latest IMUX, ABEO, CYRX, and AURA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	AURA Aura Biosciences	-$0.47	N/A	N/A	N/A	N/A	N/A
8/14/2025	Q1 2025	IMUX Immunic	-$0.19	N/A	N/A	N/A	N/A	N/A
8/11/2025	Q2 2025	ABEO Abeona Therapeutics	-$0.39	N/A	N/A	N/A	$21.71 million	N/A
8/5/2025	Q2 2025	CYRX CryoPort	-$0.20	N/A	N/A	N/A	$41.74 million	N/A
5/15/2025	Q1 2025	ABEO Abeona Therapeutics	-$0.35	-$0.24	+$0.11	-$0.24	N/A	N/A
5/15/2025	Q1 2025	AURA Aura Biosciences	-$0.47	-$0.55	-$0.08	-$0.55	N/A	N/A
5/15/2025	Q1 2025	IMUX Immunic	-$0.25	-$0.25	N/A	-$0.25	N/A	N/A
5/7/2025	Q1 2025	CYRX CryoPort	-$0.23	-$0.22	+$0.01	-$0.28	$56.19 million	$41.04 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ABEO Abeona Therapeutics	N/A	N/A	N/A	N/A	N/A
AURA Aura Biosciences	N/A	N/A	N/A	N/A	N/A
CYRX CryoPort	N/A	N/A	N/A	N/A	N/A
IMUX Immunic	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ABEO Abeona Therapeutics	0.27	4.90	4.90
AURA Aura Biosciences	N/A	11.06	11.06
CYRX CryoPort	0.51	5.56	5.24
IMUX Immunic	N/A	0.74	0.74

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ABEO Abeona Therapeutics	80.56%
AURA Aura Biosciences	96.75%
CYRX CryoPort	92.90%
IMUX Immunic	51.82%

Insider Ownership

Company	Insider Ownership
ABEO Abeona Therapeutics	6.90%
AURA Aura Biosciences	5.40%
CYRX CryoPort	10.00%
IMUX Immunic	4.60%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ABEO Abeona Therapeutics	90	51.16 million	47.63 million	Optionable
AURA Aura Biosciences	50	50.27 million	47.55 million	Not Optionable
CYRX CryoPort	1,186	50.14 million	45.12 million	Optionable
IMUX Immunic	70	95.82 million	91.41 million	Optionable

IMUX, ABEO, CYRX, and AURA Headlines

Recent News About These Companies

Immunic board authorizes up to 35 million stock ... - Investing.com

July 13, 2025 | investing.com

Immunic, Inc. (IMUX) Latest Stock News & Headlines - Yahoo Finance

July 9, 2025 | ca.finance.yahoo.com

Immunic, Inc. (NASDAQ:IMUX) Given Consensus Rating of "Buy" by Brokerages

July 6, 2025 | marketbeat.com

Immunic CEO discusses Phase 2 multiple sclerosis study success - ICYMI

June 28, 2025 | proactiveinvestors.com

D. Boral Capital Reiterates Buy Rating for Immunic (NASDAQ:IMUX)

June 25, 2025 | marketbeat.com

Immunic reveals long-term data supporting potential of MS drug vidofludimus calcium

June 24, 2025 | proactiveinvestors.com

Immunic Reports New, Positive Long-Term Open-Label Extension Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis

June 24, 2025 | prnewswire.com

Immunic showcases MS drug data at BIO International Convention in Boston - ICYMI

June 21, 2025 | proactiveinvestors.com

Immunic, Inc. (NASDAQ:IMUX) Chairman Duane Nash Purchases 20,000 Shares

June 17, 2025 | insidertrades.com

Immunic Post-Readout: Reiterating Strong Buy As Big Drop Appears Unwarranted

June 9, 2025 | seekingalpha.com

Immunic completes Phase 3 multiple sclerosis trial enrollment - ICYMI

June 7, 2025 | proactiveinvestors.com

Immunic completes patient enrollment in Phase 3 relapsing multiple sclerosis trials

June 5, 2025 | proactiveinvestors.com

Immunic Announces Completion of Enrollment for Both Phase 3 ENSURE Trials in Relapsing MS and Presents Additional Data Underlining Positive Outcome of Phase 2 CALLIPER Trial in Progressive MS

June 5, 2025 | prnewswire.com

Immunic raises $65M in public offering to fund clinical trials

June 3, 2025 | proactiveinvestors.com

Immunic raises $65M in public offering to fund clinical trials

June 3, 2025 | proactiveinvestors.com

Immunic, Inc. Announces Closing of Oversubscribed $65 Million Underwritten Public Offering

June 3, 2025 | prnewswire.com

Immunic to Participate in Investor, Scientific and Industry Conferences in June

June 2, 2025 | prnewswire.com

Immunic announces public offering of warrants to fund trials

May 30, 2025 | investing.com

Immunic shares fall 12% after pricing of $65 million underwritten public offering to fund trials

May 29, 2025 | msn.com

Immunic unveils pricing of $65M underwritten public offering

May 29, 2025 | proactiveinvestors.com

Immunic, Inc. Announces Pricing of Oversubscribed $65 Million Underwritten Public Offering

May 29, 2025 | prnewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

IMUX, ABEO, CYRX, and AURA Company Descriptions

Abeona Therapeutics NASDAQ:ABEO

$6.65 -0.06 (-0.89%)

Closing price 04:00 PM Eastern

Extended Trading

$6.68 +0.02 (+0.38%)

As of 07:55 PM Eastern

Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B. It is also developing ABO-201 gene therapy for juvenile Batten disease; ABO-202 gene therapy for treatment of infantile Batten disease; EB-201 for for epidermolysis bullosa (EB); ABO-301 for Fanconi anemia disorder; and ABO-302 using a novel CRISPR/Cas9-based gene editing approach to gene therapy program for rare blood diseases. Further, it is involved in marketing MuGard, a mucoadhesive oral wound rinse for the management of mucositis, stomatitis, aphthous ulcers, and traumatic ulcers. Abeona Therapeutics Inc. has collaborations with EB Research Partnership and Epidermolysis Bullosa Medical Research Foundation that focus on gene therapy treatments for EB; and Brammer Bio for commercial translation of ABO-102. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was incorporated in 1989 and is based in Dallas, Texas.

Aura Biosciences NASDAQ:AURA

$7.06 +0.06 (+0.86%)

Closing price 04:00 PM Eastern

Extended Trading

$7.06 0.00 (0.00%)

As of 07:11 PM Eastern

Aura Biosciences, Inc., a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates. Its lead candidate is bel-sar, which is in late-stage clinical development for the treatment of patients with primary choroidal melanoma and other ocular oncology indications, as well as in early-stage clinical development in bladder cancer. The company also focuses on assessing the safety and efficacy of bel-sar in treating a range of other solid tumors, including bladder cancer as an alternative to bacillus calmetteguérin therapy. Aura Biosciences, Inc. was incorporated in 2009 and is headquartered in Boston, Massachusetts.

CryoPort NASDAQ:CYRX

$7.98 +0.17 (+2.18%)

Closing price 04:00 PM Eastern

Extended Trading

$7.98 0.00 (0.00%)

As of 05:50 PM Eastern

Cryoport, Inc. provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services. It also provides CRYOGENE, an unparalleled solution that offers pre-clinical temperature-controlled biological materials management services comprising specimen storage, processing, collection, and retrieval; CRYOPD, a temperature-controlled logistics solution, which include temperature-controlled packaging and transport solutions from cryogenic temperature to controlled ambient; and IntegriCell services that comprise apheresis/leukapheresis collection, Cryoshuttle transportation, cryo-process optimization and processing services. In addition, the company offers MVE Biological Solutions' Fusion cryogenic system, a self-sustaining cryogenic freezer; MVE Biological Solutions' Vario cryogenic system, a cryogenic freezer system that supports temperatures between -20°C and -150°C; Cryoport Cryoshuttle provides clients with dedicated local transportation support; and Tec4Med. Further, it provides biological specimen cryopreservation storage and maintenance; archiving, monitoring, tracking, receipt, and delivery of samples; frozen biological specimens transportation; and incoming and outgoing biological specimens management; and short-term logistics and engineering consulting services. Cryoport, Inc. was founded in 1999 and is headquartered in Brentwood, Tennessee.

Immunic NASDAQ:IMUX

$1.07 +0.07 (+7.32%)

Closing price 04:00 PM Eastern

Extended Trading

$1.08 +0.01 (+1.40%)

As of 07:42 PM Eastern

Immunic, Inc., a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis. The company is also developing IMU-856, which is entering Phase 2 clinical trial, for the restoration of the intestinal barrier function in patients suffering from gastrointestinal diseases, such as celiac disease, inflammatory bowel disease, short bowel syndrome, irritable bowel syndrome with diarrhea, and other intestinal barrier function diseases; and IMU-381, which is in preclinical trial, for the treatment of gastrointestinal diseases. Immunic, Inc. was founded in 2016 and is headquartered in New York, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time